Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

JUST IN: $NVO and OpenAI partner to transform how medicines are discovered and delivered 🔥 “This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” — said Mike Doustdar, president and CEO of Novo Nordisk. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.” OpenAI will assist Novo Nordisk in upskilling the company’s global workforce and enhancing AI literacy. The partnership will also apply OpenAI’s capabilities to improve efficiency in manufacturing, supply chain and distribution and corporate operations. Pilot programmes will launch across research & development, manufacturing and commercial operations, with full integration by the end of 2026. “AI is reshaping industries and in life sciences, it can help people live better, longer lives,” — said Sam Altman, CEO of OpenAI. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”

Heute wieder vieles grün außer diese Aktie , diese dümpelt vor sich her. Ich glaube Novo kann einfach nicht mehr steigen

Kann es sein, das der d...m ist?!

Es ist unglaublich. In ein paar Tagen heißt es dann noch, dass NN für die Herstellung der Pille drauflegen muss und deshalb der Wert auf 15 Dollar gesenkt werden muss. Ich bin grad sprachlos 😵‍💫

$NVO BMO Capital maintains its Market Perform rating on Novo Nordisk and lowers its price target to $36 c. DKK230) from $45 (ca. DKK287.50). BMO Capital estimates Q1 2026 Wegovy Pill revenue will reach $136 million, or DKK881m at an exchange rate of 0.1546. Consensus currently estimates U.S. net revenue of 1,001 million Danish kroner, setting up for a potential 12% miss. BMO says the Wegovy Pill revenue growth will require further volume expansion of higher doses to beat consensus estimates in the remainder of the year.

was wurde erwartet?

Wir haben ziemlich sicher über 1mio skripte im 1. Quartal. Also kann der umsatz kaum kleiner als 149mio Dollar sein